Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure
Objective Anemia is common in patients with chronic heart failure (CHF). This study aimed to examine the frequency of iron deficiency anemia in patients with CHF. We investigated the effects of oral ferrous or ferric supplementation on prognosis of CHF and quality of life. Methods A total of 201 pat...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-07-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/0300060519847352 |
| _version_ | 1819292166294339584 |
|---|---|
| author | Snezana Ciric Zdravkovic Svetlana Petrovic Nagorni Irena Cojbasic Vesna Mitic Predrag Cvetkovic Ivan Nagorni Nenad Govedarovic Ivana Davinic Dragana Stanojevic |
| author_facet | Snezana Ciric Zdravkovic Svetlana Petrovic Nagorni Irena Cojbasic Vesna Mitic Predrag Cvetkovic Ivan Nagorni Nenad Govedarovic Ivana Davinic Dragana Stanojevic |
| author_sort | Snezana Ciric Zdravkovic |
| collection | DOAJ |
| description | Objective Anemia is common in patients with chronic heart failure (CHF). This study aimed to examine the frequency of iron deficiency anemia in patients with CHF. We investigated the effects of oral ferrous or ferric supplementation on prognosis of CHF and quality of life. Methods A total of 201 patients with chronic decompensated heart failure were enrolled in a 6-month prospective study. Patients were randomly assigned to two groups. Patients in group I (n = 100) received ferrous fumarate and those in group II (n = 101) received ferric hydroxide polymaltose complex. Quality of life was measured by the 6-minute walking test (6MWT). Results A total of 49% of the patients had iron-dependent anemia in group I and 53.3% were anemic in group II. In group I, the number of anemic patients was significantly lower at 6 months after admission compared with at initial admission (49% versus 45%). Significant improvements were observed in hemoglobin values, the 6MWT distance, and New York Heart Association class after 6 months in both groups. Conclusions Iron deficiency is a significant comorbidity in CHF, even without anemia. Iron should be replaced orally or intravenously because it significantly improves the quality of life of patients. |
| first_indexed | 2024-12-24T03:50:13Z |
| format | Article |
| id | doaj.art-e08bef7ebd2347a0945d3fc90b6506af |
| institution | Directory Open Access Journal |
| issn | 0300-0605 1473-2300 |
| language | English |
| last_indexed | 2024-12-24T03:50:13Z |
| publishDate | 2019-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj.art-e08bef7ebd2347a0945d3fc90b6506af2022-12-21T17:16:37ZengSAGE PublishingJournal of International Medical Research0300-06051473-23002019-07-014710.1177/0300060519847352Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failureSnezana Ciric ZdravkovicSvetlana Petrovic NagorniIrena CojbasicVesna MiticPredrag CvetkovicIvan NagorniNenad GovedarovicIvana DavinicDragana StanojevicObjective Anemia is common in patients with chronic heart failure (CHF). This study aimed to examine the frequency of iron deficiency anemia in patients with CHF. We investigated the effects of oral ferrous or ferric supplementation on prognosis of CHF and quality of life. Methods A total of 201 patients with chronic decompensated heart failure were enrolled in a 6-month prospective study. Patients were randomly assigned to two groups. Patients in group I (n = 100) received ferrous fumarate and those in group II (n = 101) received ferric hydroxide polymaltose complex. Quality of life was measured by the 6-minute walking test (6MWT). Results A total of 49% of the patients had iron-dependent anemia in group I and 53.3% were anemic in group II. In group I, the number of anemic patients was significantly lower at 6 months after admission compared with at initial admission (49% versus 45%). Significant improvements were observed in hemoglobin values, the 6MWT distance, and New York Heart Association class after 6 months in both groups. Conclusions Iron deficiency is a significant comorbidity in CHF, even without anemia. Iron should be replaced orally or intravenously because it significantly improves the quality of life of patients.https://doi.org/10.1177/0300060519847352 |
| spellingShingle | Snezana Ciric Zdravkovic Svetlana Petrovic Nagorni Irena Cojbasic Vesna Mitic Predrag Cvetkovic Ivan Nagorni Nenad Govedarovic Ivana Davinic Dragana Stanojevic Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure Journal of International Medical Research |
| title | Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure |
| title_full | Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure |
| title_fullStr | Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure |
| title_full_unstemmed | Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure |
| title_short | Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure |
| title_sort | effects of 6 months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure |
| url | https://doi.org/10.1177/0300060519847352 |
| work_keys_str_mv | AT snezanaciriczdravkovic effectsof6monthsoforalferrousandferricsupplementtherapyinpatientswhowerehospitalizedfordecompensatedchronicheartfailure AT svetlanapetrovicnagorni effectsof6monthsoforalferrousandferricsupplementtherapyinpatientswhowerehospitalizedfordecompensatedchronicheartfailure AT irenacojbasic effectsof6monthsoforalferrousandferricsupplementtherapyinpatientswhowerehospitalizedfordecompensatedchronicheartfailure AT vesnamitic effectsof6monthsoforalferrousandferricsupplementtherapyinpatientswhowerehospitalizedfordecompensatedchronicheartfailure AT predragcvetkovic effectsof6monthsoforalferrousandferricsupplementtherapyinpatientswhowerehospitalizedfordecompensatedchronicheartfailure AT ivannagorni effectsof6monthsoforalferrousandferricsupplementtherapyinpatientswhowerehospitalizedfordecompensatedchronicheartfailure AT nenadgovedarovic effectsof6monthsoforalferrousandferricsupplementtherapyinpatientswhowerehospitalizedfordecompensatedchronicheartfailure AT ivanadavinic effectsof6monthsoforalferrousandferricsupplementtherapyinpatientswhowerehospitalizedfordecompensatedchronicheartfailure AT draganastanojevic effectsof6monthsoforalferrousandferricsupplementtherapyinpatientswhowerehospitalizedfordecompensatedchronicheartfailure |